初始不可切除肝细胞癌降期后行肝切除术患者早期复发影响因素分析及预测模型构建的多中心研究

Analysis of factors influencing early recurrence for patients with initially unresectable hepatocellular carcinoma who underwent liver resection following downstaging treatment and construction of a predictive model: a multicenter study

  • 摘要:
    目的 探讨以经导管动脉化疗栓塞术为基础的降期治疗后初始不可切除肝细胞癌患者行挽救性肝切除术后早期复发影响因素,构建其预测模型并评估预测效能。
    方法 采用回顾性队列研究方法。收集2019年1月至2021年12月海军军医大学第三附属医院(上海东方肝胆外科医院)等全国4家医院收治的305例初始不可切除肝细胞癌患者临床病理资料;男286例,女19例;年龄为(48.7±10.4)岁。2019年1月至2020年12月收治的133例患者为训练集;2021年1―12月收治的172例患者为验证集。观察指标:(1)肝细胞癌患者术后无复发生存情况。(2)肝细胞癌患者术后早期复发的影响因素分析。(3)预测模型的构建和效能评价。正态分布的计量资料组间比较采用独立样本t检验。计数资料组间比较采用χ²检验。等级资料组间比较采用秩和检验。采用Cox回归模型进行单因素和多因素分析。采用Kaplan-Meier法计算生存率,Log-rank检验进行生存分析。采用一致性指数(C-index)、时间依赖性受试者工作特征曲线下面积评价模型的预测效能;校准曲线评估模型的准确性;决策曲线评估模型的总体净收益。
    结果 (1)肝细胞癌患者术后无复发生存情况。133例训练集肝细胞癌患者无复发生存时间为10.0(1.5~24.0)个月,1、2年无复发生存率分别为47.3%、36.8%。172例验证集患者无复发生存时间为11.0(1.0~24.0)个月,1、2年无复发生存率分别为51.7%、37.2%。两组患者无复发生存情况比较,差异无统计学意义(χ²=0.075,P>0.05)。(2)肝细胞癌患者术后早期复发的影响因素分析。多因素分析结果显示:降期治疗前肿瘤负荷,挽救性肝切除术前白蛋白-胆红素评分分级、甲胎蛋白半衰期、肿瘤反应均是肝细胞癌患者术后早期复发的独立影响因素[风险比=3.212、2.526、2.304、1.575,95%可信区间(CI)为1.262~8.175、1.324~4.818、1.477~3.595、1.138~2.180,P<0.05]。(3)预测模型的构建和效能评价。根据多因素分析结果构建患者术后早期复发列线图预测模型。训练集和验证集列线图预测模型的C-index分别为0.786和0.734。训练集列线图预测模型的12、18、24个月无复发生存率受试者工作特征曲线下面积分别为0.890(95%CI为0.836~0.944)、0.895(95%CI为0.842~0.947)、0.887(95%CI为0.831~0.942);验证集上述指标分别为0.845(95%CI为0.781~0.909)、0.888(95%CI为0.826~0.950)、0.919(95%CI为0.870~0.968)。校准曲线结果显示:列线图预测模型的预测结果与实际结果具有较高的一致性。决策曲线结果显示:阈值为0.10~0.50,列线图预测模型总体净收益较好。
    结论 降期治疗前肿瘤负荷,挽救性肝切除术前白蛋白-胆红素评分分级、甲胎蛋白半衰期、肿瘤反应是初始不可切除肝细胞癌降期治疗后行挽救性肝切除术患者早期复发的独立影响因素,基于此构建的预测模型可有效评估该类患者的预后。

     

    Abstract:
    Objective To investigate the factors influencing early recurrence for patients with initially unresectable hepatocellular carcinoma (HCC) who underwent salvage liver resection (SLR) following transcatheter arterial chemoembolization-based downstaging treatment, and construct a predictive model to evaluate its predicting performance.
    Methods The retrospective cohort study was constructed. The clinicopathological data of 305 patients with initially unresectable HCC who were admitted to 4 medical centers in China, including the Third Affiliated Hospital of Naval Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital) et al, from January 2019 to December 2021 were collected. There were 286 males and 19 females, aged (48.7±10.4)years. A total of 133 patients who were admitted from January 2019 to December 2020 were set as the training cohort, and the other 172 patients who were admitted from January to December 2021 were set as the validation cohort. Observation indicators: (1) postoperative recurrence-free survival in HCC patients; (2) analysis of factors influencing postoperative early recurrence in HCC patients; (3) construction and validation of the predictive model. Comparison of measurement data with normal distribution between groups was conducted using the independent sample t test. Comparison of count data between groups was conducted using the chi-square test. Comparison of ordinal data was conducted using the rank sum test. Univariate and multivariate analyses were conducted using the Cox regression model. The Kaplan-Meier method was used to calculate survival. The Log-rank test was used for survival analysis. The predicting performance of the model was evaluated using the concordance index (C-index) and the area under curve (AUC) of time-dependent receiver operating characteristic (ROC) curve, and the accuracy of the model was validated using the calibration curve. The total net gain of the model was evaluated using the decision curve.
    Results (1) Postoperative recurrence-free survival in HCC patients. The recurrence-free survival time of 133 HCC patients in the training cohort was 10.0(range, 1.5-24.0)months, with 1-, 2-year recurrence-free survival rate of 47.3% and 36.8%. The recurrence-free survival time of 172 HCC patients in the validation cohort was 11.0(range, 1.0-24.0)months, with 1-, 2-year recurrence-free survival rate of 51.7% and 37.2%. There was no significant difference in recurrence-free survival between patients in the training cohort and the validation cohort (χ2=0.075, P>0.05). (2) Analysis of factors influencing postoperative early recur-rence in HCC patients. Results of multivariate analysis showed that tumor burden prior to down-staging treatment, grade of albumin-bilirubin (ALBI) score prior to SLR, alpha-fetoprotein (AFP) half-life prior to SLR, and tumor response prior to SLR were independent factors influencing early recurrence in HCC patients after surgery hazard ratio=3.212, 2.526, 2.304, 1.575, 95% confidence interal (CI) as 1.262-8.175, 1.324-4.818, 1.477-3.595, 1.138-2.180, P<0.05. (3) Construction and validation of the predictive model. A nomogram predictive model for postoperative early recurrence was constructed base on the results of multivariate analysis. The C-index of predictive model was 0.786 for the training cohort and 0.734 for the validation cohort. The AUC of ROC curve of nomogram predictive model for 12-, 18-, and 24-month recurrence-free survival rate in the training cohort were 0.890 (95%CI as 0.836-0.944), 0.895 (95%CI as 0.842-0.947), and 0.887 (95%CI as 0.831-0.942), respectively. The AUC of ROC curve of nomogram predictive model for 12-, 18-, and 24-month recurrence-free survival rate in the validation cohort were 0.845 (95%CI as 0.781-0.909, 0.888 (95%CI as 0.826-0.950), and 0.919 (95%CI as 0.870-0.968), respectively. Results of calibration curve showed high consistency between the predicted results of nomogram predictive model and actual outcomes. Results of decision curve showed the nomogram predictive model with a good total net gain at a threshold of 0.10-0.50.
    Conclusions Tumor burden prior to downstaging treatment, grade of ALBI score prior to SLR, AFP half-life prior to SLR, and tumor response prior to SLR are independent factors influencing early recurrence in initially unresectable HCC patients undergoing SLR following downstaging treatment. The nomogram predictive model based on these factors can effectively evaluate the prognosis of this patient population.

     

/

返回文章
返回